OverviewSuggest Edit

IQVIA Holdings is a company that provides analytics, technology solutions, and contract research services. It focuses on a range of life science-related industries, including biopharma, MedTech, generics, consumer health, etc. The company was formed as a result of a merger between IMS Health and Quintiles.
TypePublic
Founded2016
HQDanbury, CT, US
Websiteiqvia.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Dec 2020)70,000(+5%)
Job Openings8,569
Revenue (FY, 2020)$11.4 B(+3%)
Share Price (May 2021)$228(-1%)
Cybersecurity ratingCMore

Key People/Management at IQVIA

Ari Bousbib

Ari Bousbib

Chairman and Chief Executive Officer
Ron Bruehlman

Ron Bruehlman

Executive Vice President and Chief Financial Officer
Nick Childs

Nick Childs

Senior Vice President, Investor Relations and Corporate Communications
Trudy Stein

Trudy Stein

Executive Vice President and Chief Human Resources Officer
Karl Guenault

Karl Guenault

Senior Vice President and Chief Information Officer
Jim Berkshire

Jim Berkshire

Senior Vice President, Business Operations
Show more

IQVIA Office Locations

IQVIA has offices in Danbury, Durham, Hydra, Buenos Aires and in 105 other locations
Danbury, CT, US (HQ)
83 Wooster Heights
Durham, NC, US
4820 Emperor Blvd
Hydra, DZ
Cité Sellier, Coopérative Immobilière Mohamed Boudiaf N°18, 1er étage
Buenos Aires, AR
7° piso, Av. Leandro N. Alem 1050
Melbourne, AU
Level 2/606 St Kilda Rd
Sydney, AU
Level 8, 201 Pacific Highway St Leonards
Show all (118)

IQVIA Financials and Metrics

IQVIA Revenue

Embed Graph
View revenue for all periods
IQVIA's revenue was reported to be $11.36 b in FY, 2020 which is a 2.4% increase from the previous period.
USD

Revenue (Q1, 2021)

3.4b

Gross profit (Q1, 2021)

1.1b

Gross profit margin (Q1, 2021), %

32.7%

Net income (Q1, 2021)

217.0m

EBIT (Q1, 2021)

342.0m

Market capitalization (12-May-2021)

43.7b

Closing stock price (12-May-2021)

228.0

Cash (31-Mar-2021)

2.3b

EV

54.0b
IQVIA's current market capitalization is $43.7 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

10.4b11.1b11.4b

Revenue growth, %

7%6%2%

Cost of goods sold

6.7b7.3b7.5b

Gross profit

3.7b3.8b3.9b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

2.7b2.7b2.8b2.8b2.5b2.8b3.4b

Cost of goods sold

1.7b1.8b1.9b1.8b1.7b1.8b2.3b

Gross profit

936.0m941.0m917.0m930.0m817.0m986.0m1.1b

Gross profit Margin, %

35%34%33%34%32%35%33%
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

891.0m837.0m1.8b

Accounts Receivable

2.4b2.6b2.4b

Prepaid Expenses

151.0m138.0m159.0m

Current Assets

3.9b4.1b5.1b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

936.0m938.0m863.0m927.0m1.1b1.5b2.3b

Accounts Receivable

2.5b2.4b2.5b2.6b2.4b2.4b2.4b

Prepaid Expenses

153.0m180.0m150.0m173.0m146.0m165.0m159.0m

Current Assets

4.0b4.0b4.0b4.3b4.2b4.6b5.6b
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

284.0m227.0m308.0m

Depreciation and Amortization

1.1b1.2b1.3b

Accounts Payable

368.0m240.0m253.0m

Cash From Operating Activities

1.3b1.4b2.0b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

67.0m138.0m207.0m91.0m70.0m178.0m217.0m

Depreciation and Amortization

295.0m589.0m888.0m316.0m624.0m943.0m323.0m

Cash From Operating Activities

113.0m504.0m834.0m163.0m635.0m1.2b867.0m

Purchases of PP&E

(141.0m)(296.0m)(445.0m)(141.0m)(283.0m)(440.0m)(149.0m)
USDFY, 2018

EV/EBIT

44.7 x

EV/CFO

26.4 x

Revenue/Employee

179.5k

Debt/Equity

1.6 x

Debt/Assets

0.5 x

Financial Leverage

3.2 x

P/E Ratio

93.7
Show all financial metrics

IQVIA Operating Metrics

IQVIA's Customers was reported to be 10 k in FY, 2020.
FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Healthcare Workers

14 m15 m16 m20 m22 m

Countries

828384100100

Customers

5 k8 k8 k8 k10 k

Data Sources

100 k120 k140 k150 k150 k
Show all operating metrics

IQVIA Acquisitions / Subsidiaries

Company NameDateDeal Size
Q2 SolutionsApril 01, 2021
LinguamaticsFebruary 12, 2019
Advanced Health Media LLCMay 31, 2018
DrugDevNovember 16, 2017
Aileron SolutionsJuly 01, 2014
Novella Clinical LLCAugust 14, 2013
159 SOLUTIONS
159 Technology Solutions Private Ltd
Advanced Health Media Services
AHM Global Operations Inc.
Show more

IQVIA Revenue Breakdown

Embed Graph

IQVIA revenue breakdown by business segment: 42.8% from Technology & Analytics Solutions, 50.7% from Research & Development Solutions and 6.5% from Contract Sales & Medical Solutions

IQVIA revenue breakdown by geographic segment: 32.5% from Europe and Africa, 47.7% from Americas and 19.8% from Asia-Pacific

IQVIA Cybersecurity Score

Cybersecurity ratingPremium dataset

C

76/100

SecurityScorecard logo

IQVIA Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

IQVIA Online and Social Media Presence

Embed Graph

IQVIA News and Updates

U.S. District Court Issues Favorable Decision for IQVIA Against Veeva

IQVIA (NYSE:IQV), a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced that the U.S. District Court of New Jersey issued a favorable decision in its litigation with Veeva Systems, Inc. (NYSE:VEEV).

IQVIA’s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug

IQVIA (NYSE: IQV) announced today that it will collaborate with Corium, Inc – a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies – to support the launch of AZSTARYS™, which was approved by the U.S. FDA on March 2…

IQVIA Reports First-Quarter Results; Raises Full-Year 2021 Guidance

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended March 31, 2021.

Insights on the Virtual Clinical Trials Global Market to 2026 - Featuring IQVIA Holdings, ICON PLC and Dassault Systemes Among Others

Dublin, April 20, 2021 (GLOBE NEWSWIRE) -- The "Global Virtual Clinical Trials Market By Study Type, By Indication, By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering. The Global Virtual Clinical Trials Market size is expected to reac…

IQVIA to Announce First-Quarter 2021 Results on April 22, 2021

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its first-quarter 2021 financial results before the market opens on Thursday, April 22, 2021. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date.

Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the engagement of IQVIA Biotech, a contract research organization (CRO) to manage the C…
Show more

IQVIA Frequently Asked Questions

  • When was IQVIA founded?

    IQVIA was founded in 2016.

  • Who are IQVIA key executives?

    IQVIA's key executives are Ari Bousbib, Ron Bruehlman and Nick Childs.

  • How many employees does IQVIA have?

    IQVIA has 70,000 employees.

  • What is IQVIA revenue?

    Latest IQVIA annual revenue is $11.4 b.

  • What is IQVIA revenue per employee?

    Latest IQVIA revenue per employee is $162.3 k.

  • Who are IQVIA competitors?

    Competitors of IQVIA include Eurofins, ICON and PRA Health Sciences.

  • Where is IQVIA headquarters?

    IQVIA headquarters is located at 83 Wooster Heights, Danbury.

  • Where are IQVIA offices?

    IQVIA has offices in Danbury, Durham, Hydra, Buenos Aires and in 105 other locations.

  • How many offices does IQVIA have?

    IQVIA has 118 offices.